轉移性去勢抗性前列腺癌（mCRPC）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 德國轉移性去勢抵抗性前列腺癌（mCRPC）市場預計將從2025年的3.42億美元成長到2035年的5.38億美元，這反映了在不斷推出新的癌症治療方法的推動下，該市場穩步成長。
• 以下因素推動市場擴張：
• 新一代雄性激素受體抑制劑和放射性藥物的廣泛應用
• 擴大聯合療法和序貫療法的應用
• 雖然患者數量的成長相對緩慢（年複合成長率為 0.5%），但高附加價值治療方法和延長治療週期推動市場成長。
• 未來的成長取決於精準醫療方法和新型治療方法的整合是否成功，提高存活率並延緩抗藥性的產生。

轉移性去勢抗性前列腺癌（mCRPC）概述

轉移性去勢抗性前列腺癌（mCRPC）是前列腺癌的進行性且高度侵襲性階段，其特徵是儘管透過雄性激素剝奪療法將睪固酮水準降低至去勢水準，疾病仍會進展。這種情況是由持續的雄性激素受體訊號傳導和替代性抗藥性機制引起的，這些機制使得腫瘤能夠持續生長和轉移。

臨床上，轉移性去勢抵抗性攝護腺癌（mCRPC）主要轉移至骨骼及淋巴結，引起骨痛、骨折、脊髓壓迫等嚴重併發症，以及疲勞、功能障礙等全身性症狀。這些症狀嚴重影響患者的生活品質，並導致其高發病率。

目前的治療方案多種多樣，包括新一代雄性激素受體路徑抑制劑、化療、放射性藥物和支持性治療。雖然這些治療方法提高了患者的整體存活率，但大多數患者仍無法避免治療抗藥性和疾病進展，這凸顯了現有治療方法的局限性。因此，轉移性去勢抵抗性前列腺癌（mCRPC）仍然是腫瘤學創新的重點，標靶治療、免疫療法、放射性配體療法和聯合治療的研發仍在繼續，目的是延長緩解持續時間並實現個人化治療。

主要亮點

• 在義大利，預計mCRPC 患者確診人數將從2025年37,500 人，增加到2035年的39,400 人，年複合成長率為 0.5%，這是由人口老化和壽命延長所驅動的。
• 疾病進展和治療抗藥性仍然是重大挑戰，大多數患者最終都會用盡所有可用的治療方案。
• 隨著人們對精準腫瘤學、放射性配體療法和聯合療法策略的關注度不斷提高，未來的治療模式預計將發生顯著變化。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

主要企業

• Bristol-Myers Squibb
• K36 Therapeutics, Inc.
• Janux Therapeutics
• Janssen Pharmaceutical
• Celgene
• AstraZeneca
• POINT Biopharma
• Amgen
• TechnoGenesys, Inc.
• Pfizer
• Merck Sharp &Dohme LLC
• Daiichi Sankyo
• Aragon Pharmaceuticals, Inc.
• AbbVie
• BioNTech SE
• Hoffmann-La Roche
• Fusion Pharmaceuticals Inc.
• Syncromune, Inc.
• Astellas Pharma Global Development, Inc.
• Arsenal Biosciences, Inc.
• Atridia Pty Ltd.
• Shanghai AbelZeta Ltd.
• Regeneron Pharmaceuticals
• Bayer
• Novartis Pharmaceuticals
• Tasly Pharmaceutical Group Co., Ltd
• Blue Earth Therapeutics Ltd
• Inmune Bio, Inc.
• Celcuity Inc
• Pathos AI, Inc.
• IntoCell, Inc
• Orano Med LLC
• Nuvation Bio Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法 - 概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章 未滿足的需求與目標產品分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook

Thelansis's "Global Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential mCRPC treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Metastatic Castration-Resistant Prostate Cancer (mCRPC) represents an advanced and aggressive stage of prostate cancer characterized by disease progression despite castrate levels of testosterone achieved through androgen deprivation therapy. The condition is driven by persistent androgen receptor signaling and alternative resistance mechanisms, enabling continued tumor growth and metastatic spread.

Clinically, mCRPC predominantly metastasizes to bone and lymph nodes, leading to significant complications such as bone pain, fractures, spinal cord compression, and systemic symptoms including fatigue and functional decline. These manifestations substantially impact patient quality of life and contribute to high morbidity.

The current treatment landscape is multifaceted, incorporating next-generation androgen receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, and supportive care. While these therapies have improved overall survival, treatment resistance and disease progression remain inevitable for most patients, highlighting the limitations of existing options. Consequently, mCRPC remains a major focus of oncology innovation, with ongoing development of targeted therapies, immunotherapies, radioligand therapies, and combination strategies aimed at improving durability of response and personalizing treatment approaches.

Key Highlights

• In Italy, the diagnosed mCRPC patient pool is projected to increase from 37.5K in 2025 to 39.4K by 2035, indicating modest growth (0.5% CAGR) driven by aging population and improved survival.
• Disease progression and therapeutic resistance remain key challenges, with most patients eventually exhausting available treatment options.
• Increasing focus on precision oncology, radioligand therapies, and combination treatment strategies is expected to significantly evolve the future treatment landscape.

Market Overview

• The Germany mCRPC market is projected to grow from $342M in 2025 to $538M by 2035, reflecting steady growth driven by continued adoption of novel oncology therapies.
• Market expansion is supported by:
• Uptake of next-generation androgen receptor inhibitors and radiopharmaceuticals
• Increasing use of combination and sequential treatment strategies
• Despite relatively modest patient growth (0.5% CAGR), market growth is driven by high-value therapies and extended treatment duration.
• Future growth will depend on the successful integration of precision medicine approaches and novel modalities that improve survival outcomes and delay resistance.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Bristol-Myers Squibb
• K36 Therapeutics, Inc.
• Janux Therapeutics
• Janssen Pharmaceutical
• Celgene
• AstraZeneca
• POINT Biopharma
• Amgen
• TechnoGenesys, Inc.
• Pfizer
• Merck Sharp & Dohme LLC
• Daiichi Sankyo
• Aragon Pharmaceuticals, Inc.
• AbbVie
• BioNTech SE
• Hoffmann-La Roche
• Fusion Pharmaceuticals Inc.
• Syncromune, Inc.
• Astellas Pharma Global Development, Inc.
• Arsenal Biosciences, Inc.
• Atridia Pty Ltd.
• Shanghai AbelZeta Ltd.
• Regeneron Pharmaceuticals
• Bayer
• Novartis Pharmaceuticals
• Tasly Pharmaceutical Group Co., Ltd
• Blue Earth Therapeutics Ltd
• Inmune Bio, Inc.
• Celcuity Inc
• Pathos AI, Inc.
• IntoCell, Inc
• Orano Med LLC
• Nuvation Bio Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)